RE:Moderna's CEO Stephan Bancel comments on mRNA cancer vaccineA significant differentiator between Moderna's mRNA cancer vaccine candidate and ONCY's oncolytic virus pelareorep is that pelareorep is delivered through intravenous (IV) injection while Moderna's cancer vaccine can only be delivered by subcutaneous (SC) or intratumoral (IT) injection thus limiting Moderna's vaccine to accessible cancers like melanoma.